Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose

<b>Background and Aim:</b> Controlling the hepatic inflammation of metabolic dysfunction-associated steatotic liver disease (MASLD) is important to prevent serious condition. Pemafibrate, a selective peroxisome proliferator-activated receptor-α modulator, has demonstrated effectiveness at a standard...

Descripción completa

Detalles Bibliográficos

Autores principales:	Satoshi Shinozaki, Kouichi Miura, Toshiyuki Tahara, Hironori Yamamoto
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2025-02-01
Colección:	Metabolites
Materias:	non-alcoholic fatty liver disease non-alcoholic steatohepatitis pemafibrate dyslipidemia metabolic dysfunction-associated steatotic liver disease
Acceso en línea:	https://www.mdpi.com/2218-1989/15/2/100
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!